ALK and non-small cell lung carcinoma: The other ongoing NAUTIKA1 study is a multiple cohorts perioperative trial in patients with resectable stage II-III NSCLC, which investigates neoadjuvant and adjuvant alectinib in the ALK-positive cohort (20).